Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

TXMD holding history

TherapeuticsMD, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

TXMD overviewAll 13F holders of TXMDFull Q2 2026 holdings

Shares (Q2 2026)
4,660
Value
$10.3K
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of TXMD by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20264,660$10.3K<0.1%+4,329+1,307.9%AddedHolders
Q1 2026331$669<0.1%−783−70.3%ReducedHolders
Q4 20251,114$1.81K<0.1%+752+207.7%AddedHolders
Q3 2025362$390<0.1%−4,140−92.0%ReducedHolders
Q2 20254,502$5.22K<0.1%+4,327+2,472.6%AddedHolders
Q1 2025175$162<0.1%−1,837−91.3%ReducedHolders
Q4 20242,012$1.73K<0.1%−2,835−58.5%ReducedHolders
Q3 20244,847$8.05K<0.1%−4,269−46.8%ReducedHolders
Q2 20249,116$14.7K<0.1%+1,302+16.7%AddedHolders
Q1 20247,814$17.9K<0.1%+6,542+514.3%AddedHolders
Q4 20231,272$2.86K<0.1%+575+82.5%AddedHolders
Q3 2023697$2.10K<0.1%−1,675−70.6%ReducedHolders
Q2 20232,372$9.77K<0.1%−3,138−57.0%ReducedHolders
Q1 20235,510$20.7K<0.1%+5,194+1,643.7%AddedHolders
Q4 2022316$1.77K<0.1%+229+263.2%AddedHolders
Q3 202287$00.0%−18,046−99.5%ReducedHolders
Q2 202218,133$180.0K<0.1%+18,032+17,803.8%AddedConverted for a 1-for-50 splitHolders
Q1 20225,064$2.00K<0.1%−15,224−75.0%ReducedHolders
Q4 202120,288$7.00K<0.1%+1,874+10.2%AddedHolders
Q3 202118,414$14.0K<0.1%−15,976−46.5%ReducedHolders
Q2 202134,390$41.0K<0.1%+13,856+67.5%AddedHolders
Q1 202120,534$28.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.